{"DataElement":{"publicId":"2188004","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Abnormal Secretion Gonadotropin Grade","preferredDefinition":"in CTC category Endocrine, assessment of the severity of a neuroendocrine gonadotropin secretion abnormality adverse event using a graded scale.","longName":"CTC_AE_ABN_GONAD_GD","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2198326","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Abnormal Secretion Gonadotropin","preferredDefinition":"information related to the CTC adverse event of abnormal secretion gonadotropin.","longName":"CTC_AE_ABNSEC_GONAD","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2480706","version":"1","preferredName":"Common Terminology Criteria for Adverse Events","preferredDefinition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","longName":"C49704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Common Terminology Criteria for Adverse Events","conceptCode":"C49704","definition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"133A63CA-49B0-49FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-07","modifiedBy":"ONEDATA","dateModified":"2006-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2660893","version":"1","preferredName":"abnormal secretion Gonadotropin","preferredDefinition":"Vo value exists.:No value exists.","longName":"C0679330:C2273","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"abnormal secretion","conceptCode":"C0679330","definition":"Vo value exists.","evsSource":"UMLS_CUI","primaryIndicator":"No","displayOrder":"1"},{"longName":"Gonadotropin","conceptCode":"C2273","definition":"Heterodimeric glycoprotein Gonadotropin consists of alpha (common)/beta (unique) protein subunits. The alpha subunit is present in other heterodimeric glycoprotein hormones. The beta subunit confers biological specificity and stimulates ovarian synthesis of steroids (progesterone) to maintain pregnancy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"33E73C82-DBC8-5882-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2007-06-27","modifiedBy":"ONEDATA","dateModified":"2007-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EEFB86BC-7E66-3BBA-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-02-02","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2188003","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Abnormal Secretion Gonadotropin Grade","preferredDefinition":"in CTC category Endocrine, assessment of the severity of a neuroendocrine gonadotropin secretion abnormality adverse event using a graded scale.","longName":"CTC_AE_ABN_GONAD_GD","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"NUMBER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"0","valueDescription":"None at all","ValueMeaning":{"publicId":"2574138","version":"1","preferredName":"None at all","longName":"2574138","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EEA7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CLOHNES","dateModified":"2022-08-12","changeDescription":null,"administrativeNotes":"8/12/22 added alt VM for Alliance cjl;","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E1F0790C-64CD-26B6-E034-0003BA12F5E7","beginDate":"2004-08-17","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-18","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"2","valueDescription":"Symptomatic, not interfering with ADL; intervention indicated","ValueMeaning":{"publicId":"2566526","version":"1","preferredName":"Symptomatic, not interfering with ADL; intervention indicated","longName":"2566526","preferredDefinition":"Symptomatic, not interfering with ADL; intervention indicated","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D0EB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-12","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-12","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E1F0790C-64D1-26B6-E034-0003BA12F5E7","beginDate":"2003-08-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-18","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"3","valueDescription":"Symptoms interfering with ADL; osteopenia; fracture; infertility","ValueMeaning":{"publicId":"2571653","version":"1","preferredName":"Symptoms interfering with ADL; osteopenia; fracture; infertility","longName":"2571653","preferredDefinition":"Symptoms interfering with ADL; osteopenia; fracture; infertility","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E4F2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-08-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-18","modifiedBy":"SHIDED","dateModified":"2004-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E1F0790C-64D4-26B6-E034-0003BA12F5E7","beginDate":"2004-08-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-18","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"1","valueDescription":"Asymptomatic","ValueMeaning":{"publicId":"2571651","version":"1","preferredName":"Asymptomatic","longName":"2571651v1.00","preferredDefinition":"Without clinical signs or indications that raise the possibility of a particular disorder or dysfunction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Asymptomatic","conceptCode":"C3833","definition":"Without clinical signs or indications that raise the possibility of a particular disorder or dysfunction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E4F0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-08-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-18","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E1F0790C-64CF-26B6-E034-0003BA12F5E7","beginDate":"2004-08-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-18","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184299","version":"1","preferredName":"Grade","preferredDefinition":"Describes how closely a cancer resembles normal tissue of its same type, and the cancer's probable rate of growth","longName":"Grade","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-1C87-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1F06B98-2BB2-266E-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-08-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-18","modifiedBy":"REEVESD","dateModified":"2014-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2812032","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]},{"publicId":"2604617","version":"1","longName":"Submission and Reporting","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000132","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"CTC Adverse Event Neuroendocr","type":"Preferred Question Text","description":"CTC Adverse Event Neuroendocrine: gonadotropin secretion abnormality Grade","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Neuroendocrine: gonadotropin secretion abnormality Grade","url":null,"context":"CTEP"},{"name":"Source","type":"DATA_ELEMENT_SOURCE","description":"Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","url":"http://ctep.cancer.gov/reporting/ctc.html","context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E1F06D80-B5B7-2672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-08-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-18","modifiedBy":"REEVESD","dateModified":"2011-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}